Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Given the high prevalence of bone alteration in the course of HIV infection or antiretroviral
treatment and the favourable properties of raltegravir the investigators designed this pilot
randomized and controlled study. Adult female HIV-positive patients on successful treatment
with tenofovir/emtricitabine plus atazanavir plus ritonavir will be randomized either to
continue such a regimen or to switch to raltegravir plus atazanavir plus ritonavir. Bone
mineral density changes will be compared in the two groups at 48 weeks: the hypothesis is
that removing tenofovir and using tenofovir will increase bone mineral density at 48 weeks.